Jump to content

Ibandronic acid: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
BogBot (talk | contribs)
Bots
53,132 edits
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
Line 1: Line 1:
{{drugbox
{{Drugbox
| verifiedrevid = 412569720
| verifiedrevid = 412569720
| IUPAC_name = {1-hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}''bis''(phosphonic acid)
| IUPAC_name = {1-hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}''bis''(phosphonic acid)
| image = Ibradronic Acid Structural Formulae.png
| image = Ibradronic Acid Structural Formulae.png

<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|international|ibandronic-acid}}
⚫
| licence_EU = Bonviva
⚫
| licence_US = ibandronate_sodium
⚫
| pregnancy_US = C
⚫
| legal_status = Rx-only
⚫
| routes_of_administration = Oral, [[intravenous therapy|intravenous]]

<!--Pharmacokinetic data-->
⚫
| bioavailability = 0.6%
⚫
| protein_bound = 90.9 to 99.5%<br>(concentration-dependent)
⚫
| metabolism = Nil
⚫
| elimination_half-life = 10 to 60 hours
⚫
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo_Ref = {{cascite|correct|CAS}}
⚫
| CAS_number = 114084-78-5
⚫
| ATC_prefix = M05
⚫
| ATC_suffix = BA06
⚫
| PubChem = 60852
⚫
| DrugBank = APRD00231
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54839
| ChemSpiderID = 54839
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = UMD7G2653W
| UNII = UMD7G2653W
⚫
| KEGG_Ref = {{keggcite|correct|kegg}}
⚫
| InChI = 1/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
⚫
| KEGG = D08056
⚫
| InChIKey = MPBVHIBUJCELCL-UHFFFAOYAT
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 997
| ChEMBL = 997

<!--Chemical data-->
⚫
| C=9 | H=23 | N=1 | O=7 | P=2
⚫
| molecular_weight = 319.229 g/mol
⚫
| smiles = O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O
⚫
| InChI = 1/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
⚫
| InChIKey = MPBVHIBUJCELCL-UHFFFAOYAT
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
| StdInChI = 1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MPBVHIBUJCELCL-UHFFFAOYSA-N
| StdInChIKey = MPBVHIBUJCELCL-UHFFFAOYSA-N
⚫
| CAS_number = 114084-78-5
⚫
| ATC_prefix = M05
⚫
| ATC_suffix = BA06
⚫
| PubChem = 60852
⚫
| DrugBank = APRD00231
⚫
| KEGG_Ref = {{keggcite|correct|kegg}}
⚫
| KEGG = D08056
⚫
| C = 9 | H = 23 | N = 1 | O = 7 | P = 2
⚫
| molecular_weight = 319.229 g/mol
⚫
| smiles = O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O
⚫
| bioavailability = 0.6%
⚫
| protein_bound = 90.9 to 99.5%<br>(concentration-dependent)
⚫
| metabolism = Nil
⚫
| elimination_half-life = 10 to 60 hours
⚫
| excretion = [[Kidney|Renal]]
⚫
| pregnancy_US = C
⚫
| legal_status = Rx-only
⚫
| routes_of_administration = Oral, [[intravenous therapy|intravenous]]
⚫
| licence_EU =Bonviva
⚫
| licence_US =ibandronate_sodium
}}
}}
'''Ibandronic acid''' ([[International Nonproprietary Name|INN]]) or '''ibandronate sodium''' ([[United States Approved Name|USAN]]), marketed under the trade names '''Boniva''', '''Bondronat''' and '''Bonviva''', is a potent [[bisphosphonate]] [[medication|drug]] used in the prevention and treatment of [[osteoporosis]].<ref name="pmid18360577">{{cite journal |author=Bauss F, Schimmer RC |title=Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis |journal=Therapeutics and clinical risk management |volume=2 |issue=1 |pages=3–18 |year=2006 |month=March |pmid=18360577 |pmc=1661644 |doi= |url=}}</ref>
'''Ibandronic acid''' ([[International Nonproprietary Name|INN]]) or '''ibandronate sodium''' ([[United States Approved Name|USAN]]), marketed under the trade names '''Boniva''', '''Bondronat''' and '''Bonviva''', is a potent [[bisphosphonate]] [[medication|drug]] used in the prevention and treatment of [[osteoporosis]].<ref name="pmid18360577">{{cite journal |author=Bauss F, Schimmer RC |title=Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis |journal=Therapeutics and clinical risk management |volume=2 |issue=1 |pages=3–18 |year=2006 |month=March |pmid=18360577 |pmc=1661644 |doi= |url=}}</ref>

Revision as of 06:32, 31 August 2011

Ibandronic acid
Clinical data
AHFS/Drugs.comInternational Drug Names
License data
Routes of
administration		Oral, intravenous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability0.6%
Protein binding90.9 to 99.5%
(concentration-dependent)
MetabolismNil
Elimination half-life10 to 60 hours
ExcretionRenal
Identifiers
  • {1-hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}bis(phosphonic acid)
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.214.537 Edit this at Wikidata
Chemical and physical data
FormulaC9H23NO7P2
Molar mass319.229 g/mol g·mol−1
3D model (JSmol)
  • O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O
  • InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) checkY
  • Key:MPBVHIBUJCELCL-UHFFFAOYSA-N checkY
  (verify)

Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva, Bondronat and Bonviva, is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis.[1]

It may also be used to treat hypercalcemia (elevated blood calcium levels). It is Marketed and Manufactured by GlaxoSmithKline and Roche Laboratories. Global sales in 2008 were 1.1B CHF ($1.0B USD at 01/01/2009 exchange rates).[2]

Medical uses

Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. Men should not take ibandronate unless they are participating in clinical trials[3]. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.

Adverse effects

In 2008, the U.S. Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain.[4] A study conducted by the American Society of Bone and Mineral Research concluded that long term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the thigh bone. [5]

References

  1. ^ Bauss F, Schimmer RC (2006). "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and clinical risk management. 2 (1): 3–18. PMC 1661644. PMID 18360577. {{cite journal}}: Unknown parameter |month= ignored (help)
  2. ^ "Roche 2008 Annual Report" (PDF). Roche. Retrieved 2009-08-13.
  3. ^ "boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
  4. ^ "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.
  5. ^ "Drugs Commonly Prescribed for Osteoporosis Patients are Effective at Reducing Risk of Hip and Spine Fractures, But Panel Says May be Related to Unusual Thigh Bone Fractures When Used Long Term". Journal of Bone and Mineral Research=27 October 2010.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ibandronic_acid&oldid=447613844"